• Study
  • Published June 2006

Major congenital malformations after first-trimester exposure to ACE inhibitors.

This U.S. Food and Drug Administration (FDA)– and AHRQ–funded study documents the possibility of adverse effects on the fetus when mothers take angiotensin-converting enzyme (ACE) inhibitors during the first trimester of pregnancy.

Back to Top